Literature DB >> 18292448

The effects of intrathecal cyclooxygenase-1, cyclooxygenase-2, or nonselective inhibitors on pain behavior and spinal Fos-like immunoreactivity.

Il Ok Lee1, Youngsun Seo.   

Abstract

BACKGROUND: Prostaglandins are synthesized by cyclooxygenase (COX) and are thought to play an important role in nociceptive transmission in the spinal cord. Fos expression is an indicator of spinal neuron activation. We examined the role of intrathecal selective and nonspecific COX inhibitors on spinal C-Fos expression.
METHODS: To evaluate the relative contribution of COX-1 and COX-2 in nociceptive transmission in the spinal cord, we assessed the effects of the selective COX-1 inhibitor SC 560, the selective COX-2 inhibitor celecoxib, and the nonselective COX inhibitor ketorolac on formalin-evoked behavior and spinal c-Fos-like immunoreactivity (FLI). Rats received each of the drugs (30, 60, or 90 microg) intrathecally before the subcutaneous administration of formalin (5%, 50 microL) to the plantar surface of a hindpaw. The control group received vehicle intrathecally before the administration of formalin.
RESULTS: Phase 1 flinching behavior decreased in rats given celecoxib or ketorolac 90 mug. Phase 2 flinching behavior decreased in rats given all doses of ketorolac or celecoxib 90 microg (P < 0.05). The FLI was significantly reduced in rats given celecoxib or ketorolac 90 microg for laminae I-II (P < 0.05). By contrast, for laminae V-VI, only the ketorolac 60 or 90 microg treatment group demonstrated a larger decrease in FLI (P < 0.05). The FLI expression in laminae V-VI had a significant correlation with phase 2 flinching behavior (P < 0.05).
CONCLUSIONS: A dual inhibitor of COX-1 and COX-2 suppressed both responses of formalin-evoked behaviors and FLI expression of whole laminae in the lumbar spinal cord. FLI expression of laminae I-II alone may not be a good indicator of the ability to produce anti-hypersensitivity; however, the FLI of laminae V-VI correlates with phase 2 responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18292448     DOI: 10.1213/ane.0b013e318163f602

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  7 in total

1.  Activation of NMDA receptor is associated with up-regulation of COX-2 expression in the spinal dorsal horn during nociceptive inputs in rats.

Authors:  Shu-Qin Li; Yan-Li Xing; Wei-Na Chen; Shu-Ling Yue; Li Li; Wen-Bin Li
Journal:  Neurochem Res       Date:  2009-04-01       Impact factor: 3.996

Review 2.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

3.  Amylin suppresses acetic acid-induced visceral pain and spinal c-fos expression in the mouse.

Authors:  X Huang; J Yang; J K Chang; N J Dun
Journal:  Neuroscience       Date:  2009-12-01       Impact factor: 3.590

Review 4.  The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings.

Authors:  Garry G Graham; Michael J Davies; Richard O Day; Anthoulla Mohamudally; Kieran F Scott
Journal:  Inflammopharmacology       Date:  2013-05-30       Impact factor: 4.473

5.  Role of prostaglandins in spinal transmission of the exercise pressor reflex in decerebrated rats.

Authors:  A J Stone; S W Copp; M P Kaufman
Journal:  Neuroscience       Date:  2014-07-05       Impact factor: 3.590

6.  Intrathecal catheterization and drug delivery in rats to compare the analgesic effects of morphine with ketorolac.

Authors:  Subrata Basu Ray; Roman Saini; Rakesh Kumar
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2011-01

7.  Ouabain Enhances Gap Junctional Intercellular Communication by Inducing Paracrine Secretion of Prostaglandin E2.

Authors:  Alejandro Ogazon Del Toro; Lidia Jimenez; Mauricio Serrano Rubi; Marcelino Cereijido; Arturo Ponce
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.